Latham & Watkins Advises Juno Therapeutics in JW Therapeutics’ US$100 Million Series B Financing

A cross-border life sciences team represented the immunotherapy biopharmaceutical company in the transaction.

July 09, 2020

JW Therapeutics has announced the completion of a US$100 million Series B round financing. The investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec. This round of financing brings the total capital raised to over US$200 million. 

Latham & Watkins LLP represents Juno Therapeutics in the transaction with a life sciences team consisting of Bay Area partner Judith Hasko, Shanghai associate Louise Deng and Bay Area associate Peggy Ni.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.